LOS ANGELES--(EON: Enhanced Online News)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (Nasdaq: AGIO) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at email@example.com.
At the 2016 American Society of Hematology meeting, Agios revealed new information for its AG-348 and AG-519 molecules, used to treat pyruvate kinase deficiency. Agios stated that a case of Grade 2 thrombocytopenia, which reduces platelets in blood cells, was found in a patient receiving AG-519 and that after a dose of 300 mg, a serious adverse event of drug-related cholestatic hepatitis was noted in a bioavailability and food effect study. After this release, Agios stock dropped, causing investors harm.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles, dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.